Cardiovascular drug development: is it dead or just hibernating?

Keywords

Medicine, Drug development, Context (archaeology), Government (linguistics), Intensive care medicine

References

• Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.Antonio Álvarez Cañibano — 2010
• Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.G. Michael Felker, Raymond L. Benza, A. Bleakley Chandler — 2003
• Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trialsBlood Pressure Lowering Treatment Trialists’ Collaboration — 2008
• Can the pharmaceutical industry reduce attrition rates?Ismail Kola, J. Richard Landis — 2004
• Correlation between progression free survival and response rate in patients with metastatic colorectal carcinomaChristophe Louvet, Aimery de Gramont, Christophe Tournigand — 2001
• Improving the FDA's Advisory Committee ProcessEric P. Brass, William R. Hiatt — 2012
• Ethical and scientific implications of the globalization of clinical research.Seth W. Glickman, John G. McHutchison, Eric D. Peterson — 2009
• Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).Christopher M. O’Connor, Wendy A. Gattis, Barry F. Uretsky — 1999
• U.S. spending. Final 2014 budget helps science agencies rebound.Jeffrey Mervis — 2014
• Twelve-Year Follow-Up of American Women’s Awareness of Cardiovascular Disease Risk and Barriers to Heart HealthLori Mosca, Heidi Mochari‐Greenberger, Rowena J Dolor — 2010
• Cardiovascular Disease in the Developing World and Its Cost-Effective ManagementThomas A. Gaziano — 2005
• Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.Leonard Sacks, Hala Shamsuddin, Yuliya Yasinskaya — 2014
• Deconstructing the Drug Development Process: The New Face of InnovationKenneth I. Kaitin — 2010
• The PCORI perspective on patient-centered outcomes research.Lori Frank, Ethan Basch, Joe V. Selby — 2014
• The unmet need for philanthropic funding of early career cardiovascular investigatorsTariq Ahmad, Richard C. Becker — 2014
• Heart Disease and Stroke Statistics—2014 UpdateAlan S. Go, Dariush Mozaffarian, Véronique L. Roger — 2013
• Prospects for Rapid Advances in the Development of New Medicines for Special Medical NeedsC-P Milne — 2013
• Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.Debra S. Echt, Philip R. Liebson, L. Brent Mitchell — 1991
• Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled TrialDavid G. Daniel — 1999
• A taxonomy for regulatory uncertainty—application to the European Emission Trading SchemeVolker H. Hoffmann, Thomas Trautmann, Malte Schneider — 2008

Cited by

• Overcoming Barriers to Development of Novel Therapies for Cardiovascular DiseaseJesús Ibáñez Peña — 2019
• Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over TimeRobert M. Kaplan, Veronica L. Irvin — 2015
• Which Should Be the Control Arm in Trials of Antiplatelet Therapies?Íñigo Lozano, Juan Rondán, José M. Vegas — 2015
• Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart DiseasePhilippa J. Talmud, Michael V. Holmes — 2015
• Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the LandscapeElliott M. Antman, Emelia J. Benjamin, Robert A. Harrington — 2015
• Could androgens be relevant to partly explain why men have lower life expectancy than women?C. Mary Schooling — 2015
• Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3.David D. Waters, Katherine H. Chau — 2016
• Innovative Target Therapies Are Able to Block the Inflammation Associated with Dysfunction of the Cholesterol Biosynthesis PathwayAnnalisa Marcuzzi, Elisa Piscianz, Claudia Loganes — 2015
• Pharmacogenomics to Revive Drug Development in Cardiovascular DiseaseMarie‐Pierre Dubé, Simon de Denus, Jean‐Claude Tardif — 2016
• State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases: Preface to SI Non-coding RNAs in cardiovascular disease.León J. De Windt, Thomas Thum — 2015
• Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic riskVinicius Tragante, Folkert W. Asselbergs, Daniel I. Swerdlow — 2016
• Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both WorldsRobert J. Mentz, Adrian F. Hernandez, Lisa G. Berdan — 2016
• Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?Eduardo Pimenta, David A. Calhoun — 2016
• Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.Ravi B. Patel, Muthiah Vaduganathan, Ayman Samman‐Tahhan — 2016
• Unbelievable Folly of Clinical Trials in Heart Failure: The Inconvenient Truth About How Investigators and Guidelines Weigh Evidence.Milton Packer — 2016
• Bridging the Academia/Industry Chasm: Proposed SolutionsPaul Beninger, Marcia M. Boumil, Deeb N. Salem — 2016
• Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic GrowthBalakrishnan Ganapathy, Nikitha Nandhagopal, Brian D. Polizzotti — 2016
• A novel TRPV4-specific agonist inhibits monocyte adhesion and atherosclerosisSuowen Xu, Bin Liu, Meimei Yin — 2016
• Sustainability of the Health System: Beyond Cost-effectiveness Analyses.Íñigo Lozano, Juan Rondán, José M. Vegas — 2016
• Sostenibilidad del sistema sanitario: más allá de los análisis de coste-efectividadÍñigo Lozano, Juan Rondán, José M. Vegas — 2016

Related papers

• People's Drug Guide to Deadly Drug Interactions Focuses on Drug/Drug, Drug/Food, and Drug/Vitamin Interactions:J. Shadley — 1998
• Me-too drug,me-better drug and me-new drug in drug R&DZhu Bao-quan — 2009
• The People's Guide to Deadly Drug Interactions: How to Protect Yourself from Life-Threatening Drug/Drug, Drug/Food, Drug/Vitamin CombinationsStephen Adams — 1996
• [Drug-drug interactions in diabetic patients at the Department of Clinical Pharmacology].L Magulová, Tatiana Foltánová — 2009
• The role of adaptive trial designs in drug developmentFrançois Curtin, Stéphane Héritier — 2017